EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene

Song Su iD, Yuexia Bai, Yi Lu, Ying Ren iD, Wenchao Zhang, Guangyu Wang, Kai Ma, Hongwei Zhang

International Journal of Developmental Neuroscience · 2025

DOI: 10.1002/jdn.70049 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Developmental Neuroscience, 2025. Verfasst von Song Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Mutation, Neurofibromin 1, Benzimidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 ( NF1 ) is an autosomal dominant genetic disorder, with plexiform neurofibromas occurring in approximately 20%–50% of patients. A 12‐year‐old girl underwent surgery due to unbearable pain caused by diffuse neurofibromas. Postoperatively, the girl exhibited rapid growth and extremely extensive plexiform neurofibromas, with multiple plexiform neurofibromas that were inoperable. Through high‐throughput sequencing (HTS), genetic molecular analysis was conducted on the peripheral blood samples of the child, and it was found that there was a splice site mutation c.3113 + 1G > A in the NF1 gene. Additionally, we identified a pathogenic variant c.2033dup (Ile679Aspfs*21), citing ClinVar and PMID: 77655472 to confirm its established pathogenicity in the paraffin‐embedded section sample of the diffuse neurofibroma, which was exclusively found in the girl's plexiform neurofibroma. This ‘second‐hit’ mutation could explain the rapid growth of the diffuse neurofibroma. The patient was effectively treated with oral administration of the selective MEK inhibitor selumetinib, resulting in rapid tumour regression. The treatment has shown promising efficacy against the rapid tumour growth induced by the patient's ‘second‐hit’ mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1MutationNeurofibromin 1BenzimidazolesGenes, Neurofibromatosis 1HumansFemaleChildNeurofibroma, Plexiform

Stichwörter der Autor:innen

neurofibromatosis type‐1plexiform neurofibromasecond hit variantselumetinibwhole exome sequencing

Substanzen

AZD 6244Neurofibromin 1BenzimidazolesNF1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
  • Department of Neurology, Jinan Children's Hospital, Jinan, Shandong, China.
  • Department of Pathology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
  • Department of Pathology, Jinan Children's Hospital, Jinan, Shandong, China.
  • Department of Medical Imaging, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
  • Department of Medical Imaging, Jinan Children's Hospital, Jinan, Shandong, China.

ORCID-Profile: Song Su, Ying Ren

Zitieren

APA

Su, S., Bai, Y., Lu, Y., Ren, Y., Zhang, W., Wang, G., Ma, K., & Zhang, H. (2025). Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene. International Journal of Developmental Neuroscience. https://doi.org/10.1002/jdn.70049

Vancouver

Su S, Bai Y, Lu Y, Ren Y, Zhang W, Wang G, et al. Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene. International Journal of Developmental Neuroscience. 2025. doi:10.1002/jdn.70049

BibTeX
@article{Su2025,
  author = {Su, Song and Bai, Yuexia and Lu, Yi and Ren, Ying and Zhang, Wenchao and Wang, Guangyu and Ma, Kai and Zhang, Hongwei},
  title = {Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene},
  journal = {International Journal of Developmental Neuroscience},
  year = {2025},
  doi = {10.1002/jdn.70049}
}
Kostenlos starten →